Updated data show emavusertib plus BTKI achieves high response rates in both BTKI-naive (86% ORR) and BTKI-experienced (26% ORR) PCNSL patients, with durable responses and regulatory support for accelerated approval. CLL studies are enrolling rapidly, aiming to improve outcomes via dual pathway blockade.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.